Nerandomilast: First Approval.

已完结 10 由 Gromi 发布于 2026/3/2 17:59:33

DOI:10.1007/s40265-026-02288-z
作者：Michael B Brown
文献类型：期刊论文
补充材料：只需要正文

Springer

Abstract：Nerandomilast (JASCAYD®) is an oral selective phosphodiesterase (PDE) 4B inhibitor developed by Boehringer Ingelheim Pharmaceuticals, Inc. for the treatment of lung fibrosis. It received its

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileySerum and urine metabolomics based on UPLC–QTOF/MS reveal the effect and potential mechanism of “schisandra–evodia” herb pair in the treatment of Alzheimer's disease